Episode Details

Back to Episodes
Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment

Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment

Published 1 year, 9 months ago
Description
Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us